SCHEMBL12876124

SCHEMBL12876124

CCOC(=O)c1cnn(Cc2nc(-c3cc(C)cc(C#Cc4cccnc4)c3)cs2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.47
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.36
GAA P10253 1/20 0.36
AKT1 P31749 1/20 0.36
CNKSR1 Q969H4 1/20 0.36
GRM2 Q14416 1/20 0.36
CDC7 O00311 1/20 0.36
DBF4 Q9UBU7 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 2/20 0.35
DCTPP1 Q9H773 1/20 0.35
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876187 0.90 GRM5 (0.38) GRM5KMT2AGAAAKT1ADORA3
SCHEMBL1197810 0.90 GRM5 (0.46) GRM5MAPK1KMT2AL3MBTL1GAA
SCHEMBL12876298 0.88 MAPK1 (0.36) GRM5MAPK1KMT2AL3MBTL1GAA
SCHEMBL12876288 0.88 MAPK1 (0.37) GRM5MAPK1KMT2AL3MBTL1GAA
SCHEMBL12876290 0.87 MAPK1 (0.38) GRM5MAPK1KMT2AL3MBTL1GAA
SCHEMBL12876280 0.86 GRM2 (0.36) GRM5MAPK1KMT2AL3MBTL1GAA
SCHEMBL12875915 0.85 MAPK1 (0.44) GRM5MAPK1L3MBTL1GAAAKT1
SCHEMBL12876283 0.85 GRM2 (0.38) MAPK1KMT2AL3MBTL1GAAAKT1
SCHEMBL12876132 0.84 L3MBTL1 (0.38) GRM5MAPK1KMT2AL3MBTL1GAA
SCHEMBL12876120 0.83 MMP13 (0.46) GRM5KMT2AL3MBTL1GAAAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A GRM5 788/4885MAPK1 255/4885KMT2A 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.